1. Circulating tachykinins (Substance P, neurokinin A, neuropeptide K) and the carcinoid flush;Conlon, J.M.; Deacon, C.F.; Richter, G.; Stockmann, F.; Creutzfeldt, W.;Scand J Gastroenterol,1987
2. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome;Oberg, K.; Norheim, I.; Theodorsson, E.; Ahlman, H.; Lundqvist, G.; Wide, L.;J Clin Endocrinol Metab,1989
3. Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management;Vinik, A.I.; Thompson, N.; Eckhauser, F.; Moattari, A.R.;Acta Oncol; 28: Fasc 3,1989
4. Treatment of the carcinoid tumour and the malignant carcinoid syndrome;Moertel, C.G.;J Clin Oncol,1983
5. Therapy for symptoms in the carcinoid syndrome;Coupe, M.; Levi, S.; Ellis, M.;Q J Med,1989